Eicosis LLC

Davis, CA

UEI
EM8CCFVCTV69
CAGE
6TV05
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Woman Owned Small Business
  • Woman Owned Business
  • Limited Liability Company
Entity structure
Other
SAM.gov registration date
Physical address
225 B St #14, Davis, CA 95616, USA
Website
eicosis.com
Employees
1-10
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Identification of mechanism-based therapies to treat arrhythmogenic cardiomyopathy by resolving perturbations in… R43HL164226 National Heart Lung and Blood Institute (NIH) $837,408
Development of a soluble epoxide hydrolase inhibitor to spare or replace opioid analgesics UH3DA048767 National Institute on Drug Abuse (NIH) $22,083,994
Development of a soluble epoxide hydrolase inhibitor to spare or replace opioid analgesics UG3DA048767 National Institute on Drug Abuse (NIH) $6,082,654
Inhibiting soluble epoxide hydrolase as a treatment for chemotherapy inducedperipheral neuropathic pain R43CA233371 National Cancer Institute (NIH) $264,216
Development of an oral analgesic for neuropathic pain UH2NS094258 National Institute of Neurological Disorders and Stroke (NIH) $270,975

Latest 5 listed here. See the rest on GovTribe.

Grant subawards

Prime recipient Prime award Amount Awarded
Augusta University Research Institute, Inc. EicOsis will be responsible for providing study drug and overseeing regulatory interactions. EicOsis will also analyze PK and PD samples from the clinical trial… W81XWH2110288 $377,254
Augusta University Research Institute, Inc. EicOsis will be responsible for providing study drug and overseeing regulatory interactions. EicOsis will also analyze PK and PD samples from the clinical trial… W81XWH2110288 $400,000
Augusta University Research Institute, Inc. EicOsis will be responsible for providing study drug and overseeing regulatory interactions. EicOsis will also analyze PK and PD samples from the clinical trial… W81XWH2110288 $475,000
Augusta University Research Institute, Inc. EicOsis will be responsible for providing study drug and overseeing regulatory interactions. EicOsis will also analyze PK and PD samples from the clinical trial… W81XWH2110288 $475,000

Similar vendors

Vendor Location Primary NAICS
Regulonix LLC UEI RZ32MNG7DH93 Gainesville, FL 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Palion Therapeutics UEI E6GKXJ7MWV68 New York, NY 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Adepthera LLC UEI QDWUGUNKHMT5 Palo Alto, CA 325412 Pharmaceutical Preparation Manufacturing
Purine Pharmaceuticals Inc. UEI K1FBL8EVSSK6 Gillette, NJ 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Raft Pharmaceuticals LLC UEI KD1LJTFV7DN8 San Diego, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Here is a detailed, two paragraph summary on Eicosis LLC - doing business as Eicosis:

Eicosis LLC, registered as a partnership or limited liability partnership, is a for-profit, veteran owned business focused on developing novel, safe, and effective oral treatments for patients suffering from pain and inflammatory conditions. Through federal grants, Eicosis provides pharmaceutical research and development services related to soluble epoxide hydrolase inhibitors.

Eicosis has received over $9 million in federal grant awards to support the development of its soluble epoxide hydrolase inhibitor compound EC5026 as a non-opioid analgesic for neuropathic pain. Major funding has been provided via a cooperative agreement with the National Institute on Drug Abuse to conduct preclinical studies and early stage human clinical trials examining EC5026's efficacy in replacing and dose sparing opioids for chronic pain. Additional grants were awarded by the National Institute of Neurological Disorders and Stroke to investigate EC5026 as a treatment for chemotherapy-induced peripheral neuropathic pain and for opioid sparing in general chronic pain conditions. Eicosis also received a project grant from the National Heart, Lung and Blood Institute to study mechanism-based therapies involving EC5026 for arrhythmogenic cardiomyopathy. Through its grant project portfolio, Eicosis aims to validate and advance EC5026 as an alternative to opioids and NSAIDs for certain pain conditions.

Quick answers

Is Eicosis LLC registered in SAM.gov?

Yes. Eicosis LLC's SAM.gov registration is active through June 22, 2027.

What is Eicosis LLC's most recent federal award?

Eicosis LLC's most recent federal grant award is Identification of mechanism-based therapies to treat arrhythmogenic cardiomyopathy by resolving perturbations in… (R43HL164226), from National Heart Lung and Blood Institute (NIH), on July 1, 2022.

On GovTribe

See Eicosis LLC's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login